GlassScriptPhysician profile
Abdulrab Aziz
NPI 1750429130
$3,405.89
in general payments reported to CMS, 2019-2025
27 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.45 · 2020: $207 · 2021: $537 · 2022: $310 · 2023: $643 · 2024: $882 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,275.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,260.00 | 2021-2025 | Resolute Onyx, Ffrangio, Symplicity G3 |
| Edwards Lifesciences Corporation | $436.92 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $350.60 | 2020-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Coroflow, Diamondback Coronary |
| Shockwave Medical, INC | $284.72 | 2020-2021 | |
| Cardiovascular Systems INC. | $161.19 | 2019-2023 | Diamondback Peripheral |
| Cardiva Medical, INC. | $124.71 | 2020-2023 | Cardiva Vascade 6/7f Vcs |
| Kestra Medical Technology Services, INC. | $94.43 | 2022-2023 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $82.38 | 2024-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $79.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $68.38 | 2021 | |
| Pfizer INC. | $62.03 | 2023-2025 | |
| Angiodynamics, INC. | $55.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $35.72 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.14 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.37 | 2022-2023 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $29.51 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $29.20 | 2021 | |
| Philips North America LLC | $27.49 | 2024 | (Az7) Lasers |
| Chiesi USA, INC. | $20.71 | 2024 | Kengreal |
| Abiomed | $19.62 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.37 | 2025 | |
| Novo Nordisk INC | $18.50 | 2023 | Ozempic |
| Biotronik INC. | $17.33 | 2022 | |
| Merck Sharp & Dohme LLC | $17.25 | 2021 | |
| Vifor Pharma, INC. | $16.91 | 2021 | |
| Boston Scientific Corporation | $16.55 | 2025 | Watchman Flx |
| Medicomp INC | $13.42 | 2023 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdulrab Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.